@article{4e7222f5f7f84c91a7a675cb32b02ed2,
title = "Trends and characteristics of hospitalizations for heart failure in the United States from 2004 to 2018",
abstract = "Aims: Hospitalization for heart failure (HF) constitutes a major healthcare and economic burden. Trends and characteristics of hospitalizations for HF for the recent years are not clear. We sought to determine the trends and characteristics of hospitalization for HF in the United States. Method and results: A retrospective analysis of the National Inpatient Sample weighted data between 1 January 2004 and 31 December 2018, which included hospitalized adults ≥ 18 years with primary discharge diagnosis of HF using International Classification of Diseases-9/10 administrative codes. Main outcomes were trends in hospitalizations for HF (per 1000 person) and inpatient mortality (%) between 2004 and 2018. Conclusions: Hospitalizations for HF have been increasing across both sexes and age groups since 2013, whereas inpatient mortality has been decreasing over the study period. Blacks have the highest risk of hospitalization for HF, and Whites have the highest in-hospital mortality. There are significant racial and geographic disparities related to hospitalizations for HF.",
keywords = "Age, Characteristics, Heart failure, Hospitalizations, Mortality, Race, Season, Sex",
author = "Salah, {Husam M.} and Minhas, {Abdul Mannan Khan} and Khan, {Muhammad Shahzeb} and Khan, {Safi U.} and Ambrosy, {Andrew P.} and Vanessa Blumer and Muthiah Vaduganathan and Greene, {Stephen J.} and Ambarish Pandey and Marat Fudim",
note = "Funding Information: S.J.G. receives research support from the American Heart Association, Amgen, AstraZeneca, Bristol‐Myers Squibb, Merck, and Novartis; serves on advisory boards for Amgen and Cytokinetics; and serves as a consultant for Amgen and Merck. A.P.A. is supported by a Mentored Patient‐Oriented Research Career Development Award (K23HL150159) through the National Heart, Lung, and Blood Institute; has received relevant research support through grants to his institution from Amarin Pharma, Inc., Abbott, and Novartis; and has received modest reimbursement for travel from Novartis. M.V. receives grant support or serves on advisory boards for American Regent, Amgen, AstraZeneca, Bayer AG, Baxter Healthcare, Boehringer Ingelheim, Cytokinetics, and Relypsa, and participates on clinical endpoint committees for studies sponsored by Galmed, Novartis, and the NIH. M.F. was supported by NHLBI K23HL151744 from the National Heart, Lung, and Blood Institute (NHLBI), the American Heart Association Grant 20IPA35310955, Mario Family Award, Duke Chair's Award, Translating Duke Health Award and Bayer. He receives consulting fees from AxonTherapies, Daxor, Edwards LifeSciences, NXT Biomedical. All other authors report no relevant disclosures. Publisher Copyright: {\textcopyright} 2022 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.",
year = "2022",
month = apr,
doi = "10.1002/ehf2.13823",
language = "English (US)",
volume = "9",
pages = "947--952",
journal = "ESC heart failure",
issn = "2055-5822",
publisher = "The Heart Failure Association of the European Society of Cardiology",
number = "2",
}